A, S., L, A., A, G., L, W., S, R., P, D., . . . E, M. (2023). Incidence of Hypertension and Blood Pressure Changes in Persons With Human Immunodeficiency Virus (HIV) at High Risk for Cardiovascular Disease Switching From Boosted Protease Inhibitors to Dolutegravir: A Post-hoc Analysis of the 96-week Randomised NEAT-022 Trial.
Citación estilo ChicagoA, Sempere, et al. Incidence of Hypertension and Blood Pressure Changes in Persons With Human Immunodeficiency Virus (HIV) At High Risk for Cardiovascular Disease Switching From Boosted Protease Inhibitors to Dolutegravir: A Post-hoc Analysis of the 96-week Randomised NEAT-022 Trial. 2023.
Cita MLAA, Sempere, et al. Incidence of Hypertension and Blood Pressure Changes in Persons With Human Immunodeficiency Virus (HIV) At High Risk for Cardiovascular Disease Switching From Boosted Protease Inhibitors to Dolutegravir: A Post-hoc Analysis of the 96-week Randomised NEAT-022 Trial. 2023.